You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,221,779


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,221,779
Title:Serotonin reuptake inhibitors as drugs having peripheral-system-restricted activity
Abstract: Novel serotonin reuptake inhibitor compounds which are designed to exert serotonin uptake inhibitory activity in the peripheral system while being devoid of CNS activity, and a process of preparing same are disclosed. Further disclosed are pharmaceutical compositions containing same and uses thereof in the treatment of medical conditions associated with peripheral serotonin levels and/or activity, and/or platelet aggregation.
Inventor(s): Rehavi; Moshe (Ramat-HaSharon, IL), Gurwitz; David (Hod-HaSharon, IL)
Assignee: Ramot at Tel-Aviv University Ltd. (Tel-Aviv, IL)
Application Number:12/308,671
Patent Claims:1. A serotonin reuptake inhibitor (SRI) compound comprising citalopram being modified so as to comprise at least one positively charged group, said at least one positively charged group being a quaternary ammonium group, wherein said quaternary ammonium group has the formula: --(NR.sub.1R.sub.2R.sub.3).sup.+Z.sup.- wherein: Z is an organic or inorganic anion; R.sub.1 and R.sub.2 are each methyl; and R.sub.3 is alkyl having from 1 to 4 carbon atoms.

2. The SRI compound of claim 1, wherein Z is an organic or inorganic anion selected from chloride, bromide, oxalate, maleate, mesylate and iodide.

3. The SRI compound of claim 1, wherein R.sub.3 is methyl.

4. A process of preparing the SRI compound of claim 1, the process comprising N-alkylating a free amine group in said citalopram.

5. A pharmaceutical composition comprising, as an active ingredient, the SRI compound of claim 1 and a pharmaceutically acceptable carrier.

6. The composition of claim 5, further comprising an additional therapeutically active agent.

7. The composition of claim 6, wherein said additional therapeutically active agent is anti-platelet agent.

8. The composition of claim 7, wherein said anti-platelet agent is selected from the group consisting of aspirin, clopidogrel, abciximab, argatroban, cilostazol, danaparoid, dazoxiben, dipyridamole, eptifibatide, ticlopidine and tirofiban.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.